Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation.
about
Cells infected with scrapie and Creutzfeldt-Jakob disease agents produce intracellular 25-nm virus-like particlesCholesterol balance in prion diseases and Alzheimer's diseaseTetracyclines affect prion infectivity.Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neuronsAmphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures.Agent-specific Shadoo responses in transmissible encephalopathies.Neuroinvasion by a Creutzfeldt-Jakob disease agent in the absence of B cells and follicular dendritic cellsSpiroplasma sp. 16S rDNA in Creutzfeldt-Jakob disease and scrapie as shown by PCR and DNA sequence analysis.Virus-like interference in the latency and prevention of Creutzfeldt-Jakob disease.The transmissible spongiform encephalopathies: pathogenic mechanisms and strategies for therapeutic intervention.MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie.Altered protein folding may be the molecular basis of most cases of cystic fibrosis.Emerging therapeutic agents for transmissible spongiform encephalopathies: a review.Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent.Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent.Therapeutic approaches in treating Creutzfeldt-Jakob disease - what does the future hold?Recent advances in prion chemotherapeutics.COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform.Conserved features of intermediates in amyloid assembly determine their benign or toxic states.Attempts to restore scrapie prion infectivity after exposure to protein denaturantsEarly induction of interferon-responsive mRNAs in Creutzfeldt-Jakob diseasePrion strain- and species-dependent effects of antiprion molecules in primary neuronal culturesNucleic acid binding proteins in highly purified Creutzfeldt-Jakob disease preparations.A kinetic model for amyloid formation in the prion diseases: importance of seeding.A transmissible Creutzfeldt-Jakob disease-like agent is prevalent in the human populationLate treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals.Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection.Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells.Congo red inhibition of scrapie agent replicationAblation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies.Prions: Beyond a Single Protein.Therapies for human prion diseasesTherapeutic interventions ameliorating prion disease.De novo mammalian prion synthesis.Role of proteomics in understanding prion infection.Microglial activation varies in different models of Creutzfeldt-Jakob disease.Congo red prolongs the incubation period in scrapie-infected hamsters.Endogenous viral complexes with long RNA cosediment with the agent of Creutzfeldt-Jakob diseaseThe infectivity is dissociated from PrP accumulation in salivary gland of Creutzfeldt-Jakob disease agent-inoculated mice.The nature of the scrapie agent. Biological characteristics of scrapie in different scrapie strain-host combinations.
P2860
Q24677041-1FCD45FB-AD23-4972-A4A9-57FA72E0ADBBQ27002948-D804A380-BFB8-410A-841C-687F0A98292EQ30531528-AB06CB97-648B-4518-87D8-3E296F712E7BQ33645704-360013F5-CFA4-4747-90B5-159829176959Q33801179-BED5BFD4-CD8A-4899-BFA6-8396E3DBCB97Q33874665-87E260AF-5EA5-4132-A56C-7C4179E547A0Q33930758-638432F8-0A5E-40B4-ABAE-FFB0DBDF4E41Q33950654-7EDB23BF-1C34-42CC-9A84-3D3786AB7EDCQ34982970-80604566-435F-4C9B-8EDD-756FF6D91934Q35050425-46AC1A95-046F-4977-88EA-3A07031F1EACQ35121108-FA712BC2-3C7E-4920-9A74-15284FBB96F1Q35344873-88F2DB9F-B246-4507-A901-D7D188968217Q35591287-0B8A3D36-4043-409F-8508-59CF66F1E86CQ35851885-0259D4B9-F88D-4BCE-9F99-6A7961440156Q35924758-75A5B1EC-BD24-423F-BC34-8A204702A374Q35925559-B05E324D-CF90-441D-9401-C973235A33F2Q35944199-95C8D3B7-D8FD-42ED-AB8B-B858EC498508Q36039920-0F3E0DE2-D8FE-4EA9-9AD6-81B31D7D4089Q36094175-1FC1C0D4-52F0-460D-84BD-B5DD3F0C9C7CQ36200377-2411E2E7-44A6-416B-826E-762A464F133CQ36219135-91889E9C-C7DE-4F9A-8A10-07312D6781F0Q36315218-0274905F-EDB7-4244-8E7D-5AA4D7985249Q36371953-0F1AFEE0-1421-4CA4-8252-56EB995DB32BQ36385621-AEEDCE6D-75AC-4D8C-B055-535FA76BBCF6Q36486861-E2FD23B4-02C1-4DF3-8065-788EC5D92462Q36549164-C1F31AB3-ABCD-4230-A422-B93FFA618479Q36637324-8334155F-48C2-48BA-9D7A-C4390DF6BE5DQ36640586-03D61083-BAD6-4522-91FE-CDC27768856DQ36653932-700B3DC8-5A80-46D7-AC6F-880285B18033Q36663046-DBFCCB8E-5E10-469C-A883-00621B0D92C9Q37162363-AEFEA089-B566-416D-AE94-6CBB413C04FEQ37199225-1CB94DC2-BA18-45B6-82A5-421C4F1B8CF9Q37557690-F62EBC2F-3AC5-4D18-AFE5-AACC26BA3564Q37627076-9B0F3110-D4CC-4997-A03B-4C5201EF6F1EQ38068928-59A105A9-7F4A-45E5-B27D-B52CE103E3EBQ39594243-405B6D8E-805F-4802-9FEC-F6AED9ACC93BQ39868476-8D15A6A2-980F-417A-A35F-030868CF81B9Q40399062-2054A638-F91E-46E9-B038-6D5972E4408AQ40624288-2DB2C721-99A5-4E48-A337-DF47194B4ABEQ40671329-BCC2BEB0-89C1-48C5-97C6-3032123F3566
P2860
Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Amphotericin B treatment disso ...... e agent from PrP accumulation.
@en
Amphotericin B treatment disso ...... e agent from PrP accumulation.
@nl
type
label
Amphotericin B treatment disso ...... e agent from PrP accumulation.
@en
Amphotericin B treatment disso ...... e agent from PrP accumulation.
@nl
prefLabel
Amphotericin B treatment disso ...... e agent from PrP accumulation.
@en
Amphotericin B treatment disso ...... e agent from PrP accumulation.
@nl
P2093
P356
P1433
P1476
Amphotericin B treatment disso ...... e agent from PrP accumulation.
@en
P2093
P2888
P304
P356
10.1038/356598A0
P407
P577
1992-04-01T00:00:00Z
P6179
1037931226